Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

BACKGROUND: OnabotulinumtoxinA is effective in preventing chronic migraine (CM); however, the benefit of onabotulinumtoxinA in patients with CM with daily headache is unknown because these patients are typically excluded from clinical trials. This subanalysis of the COMPEL Study assessed the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, William B., Ivan Lopez, J., Rothrock, John F., Orejudos, Amelia, Manack Adams, Aubrey, Lipton, Richard B., Blumenfeld, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734507/
https://www.ncbi.nlm.nih.gov/pubmed/30709333
http://dx.doi.org/10.1186/s10194-018-0953-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734507/
https://www.ncbi.nlm.nih.gov/pubmed/30709333
http://dx.doi.org/10.1186/s10194-018-0953-0

Ejemplares similares